Bevacizumab
Bevacizumab is a monoclonal antibody that inhibits angiogenesis (new blood vessel formation) by binding to vascular endothelial growth factor (VEGF) and preventing it from interacting with its receptors on endothelial cells. It is primarily used to treat various cancers including colorectal, lung, kidney, and ovarian cancers by starving tumors of their blood supply.
An anti-angiogenic monoclonal antibody used in cancer treatment to inhibit tumor blood vessel growth.
Key facts at a glance
- ATC
- L01FG01
- RxNorm
- 253337
- Generic
- Bevacizumab
- Class
- atc-l01
- Brands
- Mvasi, Zirabev, Alymsys, Vegzelma, Avzivi, Jobevne, Avastin
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 5mg/kg every 2 weeks
- Maximum
- consult physician
- Frequency
- every 2 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 5mg/kg every 2 weeks
- Maximum
- consult physician
- Frequency
- every 2 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 5mg/kg every 2 weeks
- Maximum
- consult physician
- Frequency
- every 2 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
9 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks to the mother
regular fetal monitoring including ultrasound assessments
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second and third trimesteravoid if possible
avoid use during second and third trimester due to risk of fetal vascular abnormalities
comprehensive fetal monitoring and ultrasound for growth assessment
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingdiscontinue breastfeeding
do not breastfeed during bevacizumab therapy and for at least 6 months after last dose
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
elderly 65 years and olderno initial dose adjustment required
monitor closely for adverse effects particularly hypertension proteinuria and fatigue; consider dose reductions for toxicity
regular blood pressure monitoring and proteinuria checks
Use with caution and monitor for adverse effects.
pediatric_age
children and adolescentsnot recommended - not approved for pediatric use
bevacizumab is not approved for patients under 18 years due to safety concerns including growth plate abnormalities and increased risk of gastrointestinal perforation
not established for pediatric population
Use of this medication in this population requires careful consideration of risks and benefits.
renal_impairment
mild to moderate renal impairmentno dose adjustment required
no dose modification needed for mild to moderate renal impairment based on population PK analysis
monitor renal function regularly
Use with caution and monitor for adverse effects.
renal_impairment
severe renal impairmentinsufficient data
use with caution; limited clinical data available for patients with severe renal impairment
close monitoring of renal function required
hepatic_impairment
mild to moderate hepatic impairmentno dose adjustment required
no dose modification needed based on population pharmacokinetic analysis
regular liver function tests
Use with caution and monitor for adverse effects.
hepatic_impairment
severe hepatic impairmentinsufficient data
use with extreme caution; limited clinical data available; not formally studied
frequent liver function monitoring
Statistics and clinical data
Drug class
Pharmacological classification based on mechanism of action
First FDA approval
Initial approval for metastatic colorectal cancer
Common uses
Approved therapeutic indications
Mechanism of action
Primary pharmacological mechanism
Treats various cancers including metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, ovarian cancer, cervical cancer, and glioblastoma. May also be used for certain eye conditions like age-related macular degeneration.
Binds specifically to VEGF, blocking its interaction with receptors (Flt-1 and KDR) on endothelial cells. This prevents endothelial cell proliferation and inhibits new blood vessel formation, thereby limiting blood supply to tumors.
Administered by intravenous infusion. Common side effects include hypertension, proteinuria, impaired wound healing, and bleeding. Contraindicated in patients with hypersensitivity, pregnancy, and should be discontinued prior to surgery. Requires monitoring of blood pressure and renal function.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy